40 patents currently held

15 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Mar 2030. from the record

Of the 15 now held by other companies, 8 were conveyed to Novartis AG in the filing they arrived in, and 7 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Mar 2030

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030 2031 2032 2033 2034 2035 2036 2037 2038 2039 204020412042 204320442045

notable patents fee due within 90 days all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Mirac Proteins US 9,464,284

The most cited patent in this portfolio, cited by 52 later US patents, top 10% of utility patents granted in 2016 in our data. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.

Ends Mar 2030 · High confidence Also notable

Conditionally Active Chimeric Antigen Receptors for Modified T-Cells US 11,584,927

Cited by 4 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2038. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.

Ends no later than Nov 2038 · Low confidence Also notable

Conditionally Active Biological Proteins US 11,254,932

Cited by 6 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2036.

Ends May 2036 · High confidence

Formerly held, still cited

Notable

Antibody Molecules to PD-1 and Uses Thereof US 9,683,048

The most cited patent in this portfolio, cited by 288 later US patents, top 1% of utility patents granted in 2017 in our data. Protection runs to 2035.

conveyed to Costim Pharmaceuticals Inc. - now held by Novartis AG

Ends Jan 2035 · High confidence

Also notable

Antibody Molecules to PD-L1 and Uses Thereof US 9,988,452

Cited by 163 later US patents, top 1% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.

conveyed to Costim Pharmaceuticals Inc. - now held by Novartis AG

Ends Oct 2035 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Dec 25, 2026
The maintenance fee for Conditionally Active Biological Proteins (US 10,329,556) comes due Dec 25, 2026. Unpaid by Jun 25, 2027, it lapses early.
1 fee due Feb 8, 2027
The maintenance fee for Mirac Proteins (US 11,718,844) comes due Feb 8, 2027. Unpaid by Aug 9, 2027, it lapses early.
1 fee due Apr 3, 2027
The maintenance fee for Conditionally Active Polypeptides and Methods of Generating Them (US 11,773,509) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.
3 fees due Jun 5 to 26, 2027 · next Jun 5
3 fees due Aug 13 to 18, 2027 · next Aug 13

Which patents, and when each one lapses · Pro

Recent changes

1 of the patents on this record was granted since Aug 16, 2026
1 term has ended since Aug 16, 2026

What they patent

The 5 largest of its 21 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Mirac Proteins	7 in force	to Mar 2030
Conditionally Active Biological Proteins	4 in force	to Mar 2037
Simultaneous, Integrated Selection and Evolution of Antibody/Protein Performance and Expression in Production Hosts	3 in force	to Jul 2030
Conditionally Active Anti-Epcam Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof	2 in force	to Jun 2040
ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses Thereof	2 in force	to Oct 2039

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 8,709,755	Mirac Proteins In force Term ends Mar 9, 2030 · High confidence	In force	Term ends Mar 9, 2030	High confidence
US 9,464,284	Mirac Proteins In force Term ends Mar 9, 2030 · High confidence	In force	Term ends Mar 9, 2030	High confidence
US 9,637,734	Mirac Proteins In force Term ends Mar 9, 2030 · High confidence	In force	Term ends Mar 9, 2030	High confidence
US 9,637,735	Mirac Proteins In force Term ends Mar 9, 2030 · High confidence	In force	Term ends Mar 9, 2030	High confidence
US 9,994,841	Mirac Proteins In force Term ends Mar 9, 2030 · High confidence	In force	Term ends Mar 9, 2030	High confidence
US 11,718,844	Mirac Proteins In force Term ends Mar 9, 2030 · High confidence	In force	Term ends Mar 9, 2030	High confidence
US 9,982,252	Mirac Proteins In force Term ends Mar 13, 2030 · High confidence	In force	Term ends Mar 13, 2030	High confidence
US 8,859,467	Simultaneous, Integrated Selection and Evolution of Antibody/Protein Performance and Expression in Production Hosts In force Term ends Jul 16, 2030 · High confidence	In force	Term ends Jul 16, 2030	High confidence
US 10,047,357	Simultaneous, Integrated Selection and Evolution of Antibody/Protein Performance and Expression in Production Hosts In force Term ends Jul 16, 2030 · High confidence	In force	Term ends Jul 16, 2030	High confidence
US 10,920,216	Simultaneous, Integrated Selection and Evolution of Antibody/Protein Performance and Expression in Production Hosts In force Term ends Jul 16, 2030 · High confidence	In force	Term ends Jul 16, 2030	High confidence

10 of 40 patents shown.

Pro members see all 40.

Pro members: see all 40 patents

Also on record, not counted in the 40: 15 patents in force now held by others · 2 patents ended · 22 applications pending · 14 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

BioAtla Inc.